Wiley Handbook of Current and Emerging Drug Therapies, 4 Volume Set / Edition 1

Wiley Handbook of Current and Emerging Drug Therapies, 4 Volume Set / Edition 1

by John Wiley & Sons Ltd, John Wiley & Sons Inc, Inc John Wiley &. Sons
     
 

ISBN-10: 047004098X

ISBN-13: 9780470040980

Pub. Date: 12/05/2006

Publisher: Wiley

The Wiley Handbook of Current and Emerging Drug Therapies supports the information needs of research managers and scientists working in drug discovery environments in academia, industry, and government. A carefully structured program of online updating and successive print editions will ensure that the Handbook reflects the latest information on new molecular

…  See more details below

Overview

The Wiley Handbook of Current and Emerging Drug Therapies supports the information needs of research managers and scientists working in drug discovery environments in academia, industry, and government. A carefully structured program of online updating and successive print editions will ensure that the Handbook reflects the latest information on new molecular entities, clinical trials, drug approvals, and post-approval studies of new drugs. A landmark reference to support drug discovery and evidence-based medicine, the Wiley Handbook of Current and Emerging Drug Therapies will provide researchers, clinicians, and other professionals with essential scientific information on established and emerging drug treatments for common medical indications.

Product Details

ISBN-13:
9780470040980
Publisher:
Wiley
Publication date:
12/05/2006
Pages:
2664
Sales rank:
707,306
Product dimensions:
6.91(w) x 10.04(h) x 7.48(d)

Related Subjects

Table of Contents

PART I: INTRODUCTION.

The Drug Discovery Process.

Clinical Trials, Overview.

Therapeutic Area Trends in R&D of the Top 20 Pharmaceutical Companies.

PART II: ONCOLOGY.

Aggressive Non-Hodgkin's Lymphomas.

Bladder Cancer.

Breast Cancer.

Cervical Cancer.

Chronic Lymphocytic Leukemia (CLL).

Chronic Myelogenous Leukemia.

Colorectal Cancer.

Malignant Melanoma.

Multiple Myeloma.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Volume 2.

PART II: ONCOLOGY.

Non-Small-Cell Lung Cancer.

Ovarian Cancer.

Pancreatic Cancer.

Prostate Cancer.

Small-Cell Lung Cancer.

PART III: IMMUNE SYSTEM.

Allergic Rhinitis.

Asthma.

Crohn's Disease.

Psoriasis.

Rheumatoid Arthritis.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Volume 3.

PART IV. METABOLIC DISEASES.

Diabetic Retinopathy.

Dyslipidemia.

Metabolic Syndrome.

Obesity.

Osteoporosis.

Type 1 Diabetes.

Type 2 Diabetes.

PART V. INFECTIOUS DISEASES.

Acute Exacerbations of Chronic Bronchitis.

Community-Acquired Pneumonia.

Complicated Skin and Soft Tissue Infections.

Hepatitis C.

Methicillin-Resistant Staphylococcus Aureus.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Volume 4.

PART VI. EMERGING TECHNOLOGIES AND BUSINESS OPPORTUNITIES.

Data and Information Integration in Pharmaceutical R&D.

Impact of Technological Advances on Pharmaceutical Productivity.

Advances in Medicinal Chemistry and Lead Optimization.

Bio-Defense Opportunities in the Biotechnology and Pharmaceutical Industries.

Fear of Theranostics: Why an Industry Has Not Really Emerged.

Beyond Commodity Drugs: Strategic Diversification in the Generics Industry.

PART VII: GLOBAL MARKETS AND NATIONAL POLICY.

The EU Clinical Trials Directive: Impact in Europe and Beyond.

The Indian Pharmaceutical Industry in Transition: Changes and Opportunities Ahead.

Spotlight on the Australian and New Zealand Pharmaceutical and Biotechnology Industries.

Overview of the World's Major OTC Markets.

Biotech Hubs-Key Growth Engines for Drug Development.

Pharmaceutical Marketplace in Central and Eastern Europe.

Valuation Models for European Biotech.

Taking Global Action: Integrating Social Responsibility into Corporate Practices.

Global Branding Strategy: From the Blockbuster to the Targeted Model.

PART VIII: NEW OPPORTUNITIES IN DRUG DISCOVERY AND PIPELINE DEVELOPMENT.

Prospects for Genomics-Derived Drugs: New Approaches and Impact on Pharmaceutical Pipelines.

Prying Open the Pipeline: Drug Discovery and Development in the Postgenomics Era.

Glycomics: The Impact of Carbohydrates on Biological Function and the Implications for Drug Discovery.

High-Content Screening for Drug Discovery and Target Validation.

High-Throughput ADMET Screening: Improving the Efficiency of Drug Discovery.

Emerging Concepts in GPCR Research and Their Implications for Drug Discovery.

Optimizing Knowledge Management in Pharmaceutical Companies.

Cumulative Index of Drug and Molecule Names, Volumes 1-4.

Subject Index.

Cumulative Subject Index, Volumes 1-4.

Read More

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >